Neurological abnormalities in full-term asphyxiated newborns and salivary S100B testing: the "Cooperative Multitask against Brain Injury of Neonates" (CoMBINe) international study

Perinatal asphyxia (PA) is a leading cause of mortality and morbidity in newborns: its prognosis depends both on the severity of the asphyxia and on the immediate resuscitation to restore oxygen supply and blood circulation. Therefore, we investigated whether measurement of S100B, a consolidated marker of brain injury, in salivary fluid of PA newborns may constitute a useful tool for the early detection of asphyxia-related brain injury.We conducted a cross-sectional study in 292 full-term newborns admitted to our NICUs, of whom 48 suffered PA and 244 healthy controls admitted at our NICUs. Saliva S100B levels measurement longitudinally after birth; routine laboratory variables, neurological patterns, cerebral ultrasound and, magnetic resonance imaging were performed. The primary end-point was the presence of neurological abnormalities at 12-months after birth.S100B salivary levels were significantly (P3.25 MoM S100B achieved a sensitivity of 100% (CI5-95%: 89.3%-100%) and a specificity of 100% (CI5-95%: 98.6%-100%) as a single marker for predicting the occurrence of abnormal neurological outcome (area under the ROC curve: 1.000; CI5-95%: 0.987-1.0).S100B protein measurement in saliva, soon after birth, is a useful tool to identify which asphyxiated infants are at risk of neurological sequelae

Neurological abnormalities in full-term asphyxiated newborns and salivary S100B testing: the "Cooperative Multitask against Brain Injury of Neonates" (CoMBINe) international study

Perinatal asphyxia (PA) is a leading cause of mortality and morbidity in newborns: its prognosis depends both on the severity of the asphyxia and on the immediate resuscitation to restore oxygen supply and blood circulation. Therefore, we investigated whether measurement of S100B, a consolidated marker of brain injury, in salivary fluid of PA newborns may constitute a useful tool for the early detection of asphyxia-related brain injury.We conducted a cross-sectional study in 292 full-term newborns admitted to our NICUs, of whom 48 suffered PA and 244 healthy controls admitted at our NICUs. Saliva S100B levels measurement longitudinally after birth; routine laboratory variables, neurological patterns, cerebral ultrasound and, magnetic resonance imaging were performed. The primary end-point was the presence of neurological abnormalities at 12-months after birth.S100B salivary levels were significantly (P3.25 MoM S100B achieved a sensitivity of 100% (CI5-95%: 89.3%-100%) and a specificity of 100% (CI5-95%: 98.6%-100%) as a single marker for predicting the occurrence of abnormal neurological outcome (area under the ROC curve: 1.000; CI5-95%: 0.987-1.0).S100B protein measurement in saliva, soon after birth, is a useful tool to identify which asphyxiated infants are at risk of neurological sequelae

CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor

CD69 is a differentiation antigen expressed shortly after activation on T lymphocytes and other cells of haematopoietic origin, including natural killer (NK) cells. The function of CD69 on T lymphocytes acting as a costimulatory molecule in proliferation and lymphokine secretion is well established. NK cells express CD69 after activation by different stimuli such as phorbol 12-myristate 13-acetate (PMA), interleukin (IL)-2, IL-12, interferon-α (IFN-α) or anti-CD16 monoclonal antibodies (mAbs). However, although it has been shown that CD69 triggers NK-cell-mediated cytolytic activity, its effect on other NK-cell functions has not been studied. Furthermore, the possible interaction of CD69 triggering with other C-lectin type inhibitory receptors is not known. Thus, the objective of this work is to determine whether CD69-mediated NK cytotoxicity can be regulated by CD94 inhibitory receptor and the role of CD69 on other NK-cell functions different of cytotoxicity. The results show that CD69-mediated NK cytotoxicity can be abrogated by CD94 stimulation in NK cells expressing the CD94 inhibitory form of the receptor, indicating that CD94 regulates the cytotoxic events initiated by a wide variety of NK activatory receptors. We also show that anti-CD69 mAbs, not only triggered NK cytotoxicity, but also induce NK-cell proliferation, CD25 and intracellular adhesion molecule-1 (ICAM-1) expression, TNF-α production and Ca2+ mobilization in preactivated NK cells. These results suggest that CD69 plays a crucial role in NK-cell function contributing to sustain NK-cell activation, as it has been previously demonstrated in T cells

Is female sex a significant favorable prognostic factor in hepatocellular carcinoma?

OBJECTIVE: As sex favorably modulates the natural history of chronic liver diseases and the risk for neoplastic evolution, our study aimed to ascertain whether female hepatocellular carcinoma (HCC) patients are also characterized by better prognosis. METHODS: The ITA.LI.CA (Italian Liver Cancer) database was used, including 1834 HCC patients (482 females, 1352 males) that were consecutively diagnosed. The following variables were considered: age, etiology, modality of diagnosis, earlier interferon treatment, bilirubin, alpha-fetoprotein levels, constitutional syndrome, portal thrombosis, metastasis, number and size of nodules, grading, Child-Pugh class, tumor-nodes-metastases and Cancer of the Liver Italian Program staging, and treatment. RESULTS: Female HCC patients were characterized by older age (P=0.0001), higher prevalence of HCV infection (P=0.0001), diagnosis more frequently by surveillance (P=0.003), higher alpha-fetoprotein levels (P=0.0055), lower prevalence of constitutional syndrome (P=0.03), portal thrombosis (P=0.04), and metastasis (P=0.0001). HCC in females was more frequently unifocal (P=0.0001), smaller (P=0.001), well differentiated (P=0.001), and of lower Cancer of the Liver Italian Program and tumor-nodes-metastases stage (P=0.0001 and 0.0001). However, females underwent curative treatments (transplantation, resection, percutaneous ablation) in the same percentage of cases as males. Finally, females had a significantly longer survival (median 29 [95% confidence interval (CI): 24-33] vs. 24 (22-25) months, P=0.0001). The difference was sharper [median 36 (CI: 31-41] vs. 17 (CI: 15-19)] when females undergoing surveillance were compared with males diagnosed incidentally or for symptoms. The Cox model also identified sex as an independent predictor of survival. When only patients undergoing surveillance were considered, no significant difference was observed. CONCLUSION: HCC in females has better prognosis, but this is possibly more because of higher compliance with surveillance than to real biological differences

Euclid. IV. The NISP Calibration Unit

International audienceThe near-infrared calibration unit (NI-CU) onboard Euclid's Near-Infrared Spectrometer and Photometer (NISP) is the first astronomical calibration lamp based on light-emitting diodes (LEDs) to be operated in space. Euclid is a mission in ESA's 'Cosmic Vision 2015-2025' framework, to explore the dark universe and provide a next-level characterisation of the nature of gravitation, dark matter, and dark energy. Calibrating photometric and spectrometric measurements of galaxies to better than 1.5% accuracy in a survey homogeneously mapping ~14000 deg^2 of extragalactic sky requires a very detailed characterisation of near-infrared (NIR) detector properties, as well their constant monitoring in flight. To cover two of the main contributions - relative pixel-to-pixel sensitivity and non-linearity characteristics - as well as support other calibration activities, NI-CU was designed to provide spatially approximately homogeneous (=100 from ~15 ph s^-1 pixel^-1 to >1500 ph s^-1 pixel^-1. For this functionality, NI-CU is based on LEDs. We describe the rationale behind the decision and design process, describe the challenges in sourcing the right LEDs, as well as the qualification process and lessons learned. We also provide a description of the completed NI-CU, its capabilities and performance as well as its limits. NI-CU has been integrated into NISP and the Euclid satellite, and since Euclid's launch in July 2023 has started supporting survey operations

Euclid. IV. The NISP Calibration Unit

The near-infrared calibration unit (NI-CU) onboard Euclid's Near-Infrared Spectrometer and Photometer (NISP) is the first astronomical calibration lamp based on light-emitting diodes (LEDs) to be operated in space. Euclid is a mission in ESA's 'Cosmic Vision 2015-2025' framework, to explore the dark universe and provide a next-level characterisation of the nature of gravitation, dark matter, and dark energy. Calibrating photometric and spectrometric measurements of galaxies to better than 1.5% accuracy in a survey homogeneously mapping ~14000 deg^2 of extragalactic sky requires a very detailed characterisation of near-infrared (NIR) detector properties, as well their constant monitoring in flight. To cover two of the main contributions - relative pixel-to-pixel sensitivity and non-linearity characteristics - as well as support other calibration activities, NI-CU was designed to provide spatially approximately homogeneous (=100 from ~15 ph s^-1 pixel^-1 to >1500 ph s^-1 pixel^-1. For this functionality, NI-CU is based on LEDs. We describe the rationale behind the decision and design process, describe the challenges in sourcing the right LEDs, as well as the qualification process and lessons learned. We also provide a description of the completed NI-CU, its capabilities and performance as well as its limits. NI-CU has been integrated into NISP and the Euclid satellite, and since Euclid's launch in July 2023 has started supporting survey operations